PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy - Trial NCT06156878

Timeline & Enrollment

Primary Outcome

PFS,OS

Summary

Because nasopharyngeal carcinoma （NPC）is very sensitive to radiation and the specificity of
 the anatomical structure, radiotherapy has become the core treatment for NPC. Although
 induction chemotherapy combined with cisplatin-based concurrent chemoradiotherapy can
 effectively improve the overall survival and progression-free survival of NPC, such a
 sequential pattern can further exacerbate the toxic side effects of treatment, such as
 mucosal reactions and gastrointestinal toxicity. Therefore, it is particularly important to
 explore another treatment mode with high efficiency and low toxicity. Secondly, patients with
 poor response after induction chemotherapy indicate chemotherapy resistance. Whether patients
 can still benefit from concurrent platinum-based chemotherapy in the followed radiotherapy is
 doubtful. PD-1 inhibitor and anti-EGFR monoclonal antibody have proved to improve outcomes of
 head and neck cancers including EBV-related NPC, which have also showed relatively low
 toxicity. In this study, radiotherapy combined with PD-1 inhibitor and anti-EGFR monoclonal
 antibody were applied to treat patients with locally advanced NPC who were resistant to
 induction chemotherapy.

ICD-10 Classifications